JP2024534550A5 - - Google Patents

Info

Publication number
JP2024534550A5
JP2024534550A5 JP2024518167A JP2024518167A JP2024534550A5 JP 2024534550 A5 JP2024534550 A5 JP 2024534550A5 JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024534550 A5 JP2024534550 A5 JP 2024534550A5
Authority
JP
Japan
Prior art keywords
antibody molecule
pharmaceutical composition
combination
composition according
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/076268 external-priority patent/WO2023046777A1/en
Publication of JP2024534550A publication Critical patent/JP2024534550A/ja
Publication of JP2024534550A5 publication Critical patent/JP2024534550A5/ja
Pending legal-status Critical Current

Links

JP2024518167A 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用 Pending JP2024534550A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21306310.0 2021-09-22
EP21306310 2021-09-22
EP22305050 2022-01-18
EP22305050.1 2022-01-18
PCT/EP2022/076268 WO2023046777A1 (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534550A JP2024534550A (ja) 2024-09-20
JP2024534550A5 true JP2024534550A5 (enExample) 2025-09-08

Family

ID=83507478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518167A Pending JP2024534550A (ja) 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用

Country Status (10)

Country Link
US (1) US20240374719A1 (enExample)
EP (1) EP4405050A1 (enExample)
JP (1) JP2024534550A (enExample)
KR (1) KR20240067076A (enExample)
AU (1) AU2022351060A1 (enExample)
CA (1) CA3231396A1 (enExample)
IL (1) IL311234A (enExample)
MX (1) MX2024003578A (enExample)
TW (1) TW202321458A (enExample)
WO (1) WO2023046777A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765710B2 (en) * 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0820576B1 (pt) 2007-11-19 2021-10-19 Transgène S.A. Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo
EP2240573A4 (en) 2008-02-12 2011-08-31 Sanofi Pasteur Ltd METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
ES2813413T3 (es) 2011-08-05 2021-03-23 Sillajen Biotherapeutics Inc Métodos y composiciones para la producción de virus vaccina
MX2019010797A (es) * 2017-03-15 2019-10-24 Amgen Inc Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
AU2018254626B2 (en) * 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
KR20200131863A (ko) * 2018-03-13 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP7732977B2 (ja) Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
KR101838310B1 (ko) 암의 치료를 위한 인간화 항-cxcr4 항체들
JP2022514179A5 (enExample)
JP2013502913A5 (enExample)
JP2020534017A5 (enExample)
JP2024531409A5 (enExample)
RU2019104980A (ru) Анти-icos антитела
CN111388664A (zh) 干细胞增强疗法
JP2009520733A (ja) 可溶性ｃｅａに対する抵抗性を有する医薬抗体組成物
JP2021177770A (ja) ＣＤ６６ｃに特異的に結合する抗体およびその用途
CN117050165B (zh) 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途
JPWO2020067085A1 (ja) 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬
JP2024540148A5 (enExample)
JP2024538148A5 (enExample)
JP2024091656A5 (enExample)
JP7407742B2 (ja) Ｇａｓｐ－１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用
JP2024534116A5 (enExample)
JP2022512544A5 (enExample)
Takahashi et al. Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy
CN115925940B (zh) 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
Wang et al. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines
RU2024110605A (ru) Новые комбинации антител и их применение
CN114616245B (zh) 一种抗cd38的抗体及其用途
RU2824962C1 (ru) Комбинация поксвируса, кодирующего полипептиды вируса папилломы человека, и il-2 с антителом к pd-l1